glp-1 drugs long term effects Long-term Success of GLP-1s Hinges on More Than Just a Prescription GLP‑1 Long‑Term Safety: Side Effects

This gives Mounjaro a slight advantage in achieving faster weight-loss results. In a head-to-head clinical trial, Lilly reported that tirzepatide led to an average weight reduction of 20.2%, compared to 13.7% with semaglutide after 72 weeks of treatmenta 47% greater relative weight loss with tirzepatide

Separately, it is reported that GLP-1RAs mitigate weight increase incurred from psychotropic drug exposure [24]

Positioned Within Massive Market Expansion The commercial opportunity surrounding GLP-1 therapies continues to grow rapidly

Key trends in the Prescription Drug Market Rise of GLP-1 Agonists & Obesity Drugs Drugs like Ozempic (semaglutide) and Zepbound (tirzepatide) dominate growth, with the anti-obesity market projected to exceed USD 100B by 2026

Initially intended for those with Type 2 diabetes because of their effectiveness in balancing blood sugar levels and their impact on insulin sensitivity, doctors quickly realized their off-label potential for weight loss, leading to their widespread popularity today

With deep expertise in peptide engineering and large-scale biologics manufacturing, Novo Nordisk continues to expand GLP-1 innovation through next-generation injectable and oral formulations, reinforcing its leadership in chronic weight management and glycemic control